Get the Stockscreener App
220.65
0.21%
0.46
Cidara Therapeutics Inc stock is traded at $220.65, with a volume of 551.08K.
It is up +0.21% in the last 24 hours and up +105.98% over the past month.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
See More
Previous Close:
$220.19
Open:
$220.29
24h Volume:
551.08K
Relative Volume:
0.39
Market Cap:
$6.94B
Revenue:
$302.00K
Net Income/Loss:
$-117.10M
P/E Ratio:
-19.82
EPS:
-11.13
Net Cash Flow:
$-129.13M
1W Performance:
+0.13%
1M Performance:
+105.98%
6M Performance:
+809.52%
1Y Performance:
+919.64%
1-Day Range:
$220.15
$220.78
1-Week Range:
$219.60
$220.78
52-Week Range:
$15.22
$221.20
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Name
Cidara Therapeutics Inc
Sector
Industry
Phone
858-752-6170
Address
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Compare CDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
220.65 | 6.92B | 302.00K | -117.10M | -129.13M | -11.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-17-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-17-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-16-25 | Initiated | Morgan Stanley | Overweight |
| Oct-10-25 | Initiated | JP Morgan | Overweight |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Mar-12-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-27-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Nov-08-24 | Initiated | Guggenheim | Buy |
| Aug-14-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-03-21 | Resumed | H.C. Wainwright | Buy |
| Sep-22-21 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-04-21 | Initiated | Aegis Capital | Buy |
| Sep-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Jul-26-18 | Initiated | Citigroup | Buy |
| Apr-21-17 | Initiated | Raymond James | Strong Buy |
| Apr-17-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-11-17 | Resumed | Wedbush | Outperform |
| Feb-22-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-17 | Upgrade | WBB Securities | Sell → Hold |
| Dec-21-16 | Resumed | Leerink Partners | Outperform |
| Dec-19-16 | Initiated | H.C. Wainwright | Buy |
| Sep-23-16 | Downgrade | WBB Securities | Hold → Sell |
| Oct-09-15 | Upgrade | WBB Securities | Sell → Hold |
| May-11-15 | Initiated | Jefferies | Buy |
| May-11-15 | Initiated | Leerink Partners | Outperform |
| May-11-15 | Initiated | Needham | Buy |
| May-11-15 | Initiated | Wedbush | Outperform |
| Apr-23-15 | Initiated | WBB Securities | Sell |
View All
Cidara Therapeutics Inc Stock (CDTX) Latest News
Bain Capital Life Sciences Investors LLC Purchases 1,797,600 Shares of Cidara Therapeutics, Inc. $CDTX - MarketBeat
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Cidara therapeutics COO Ward sells $2.19 million in stock By Investing.com - Investing.com South Africa
Cidara therapeutics COO Ward sells $2.19 million in stock - Investing.com
CEO Stein Surrenders 2,285 Of Cidara Therapeutics Inc [CDTX] - TradingView
Cidara Therapeutics’ Earnings Call Highlights CD388 Progress - MSN
Marshall Wace LLP Buys New Stake in Cidara Therapeutics, Inc. $CDTX - MarketBeat
Analysts Shift to Hold as Cidara’s (CDTX) Recent Acquisition Deal Caps Upside - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Stempoint Capital LP Takes Position in Cidara Therapeutics, Inc. $CDTX - MarketBeat
Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump - The Motley Fool
Vivo Capital LLC Boosts Stock Position in Cidara Therapeutics, Inc. $CDTX - MarketBeat
Resolute Capital Asset Partners LLC Makes New $1.33 Million Investment in Cidara Therapeutics, Inc. $CDTX - MarketBeat
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck - Savannah Morning News
Best Biotech Stocks To Keep An Eye OnDecember 8th - MarketBeat
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SMLR, MRSN, CDTX, and RYI - Sahm
Cidara Therapeutics (CDTX) price target increased by 18.53% to 220.19 - MSN
Is This Pharmaceutical Giant a Buy After a Major Acquisition? - Finviz
How Cidara Therapeutics Inc. (20D0) stock behaves under inflation pressureMarket Trend Report & Growth-Oriented Investment Plans - Newser
Best Biotech Stocks To ResearchDecember 1st - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Sets New 1-Year HighStill a Buy? - MarketBeat
Cidara Therapeutics Earnings Notes - Trefis
Cidara Therapeutics stock hits 52-week high at 220.49 USD By Investing.com - Investing.com South Africa
Cidara Therapeutics stock hits 52-week high at 220.49 USD - Investing.com
Quadrature Capital Ltd Takes Position in Cidara Therapeutics, Inc. $CDTX - MarketBeat
How resilient is Cidara Therapeutics Inc. stock in market downturnsNew Guidance & High Accuracy Trade Signal Alerts - Newser
Merck Commits $9.2 Billion to Acquire Cidara Therapeutics - MSN
Gainers Report: How resilient is Cidara Therapeutics Inc stock in market downturns2025 Top Gainers & Expert-Curated Trade Recommendations - BỘ NỘI VỤ
The American biopharm company Merck plans to raise $8 billion through the sale of bonds - AKM.RU
Cidara Therapeutics (NASDAQ:CDTX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Ensign Peak Advisors Inc Takes $244,000 Position in Cidara Therapeutics, Inc. $CDTX - MarketBeat
Will Cidara Therapeutics Inc. (20D0) stock hit Wall Street targetsEarnings Recap Report & AI Driven Stock Price Forecasts - Newser
Merck Kicks Off US Dollar Bond Sale to Help Fund Cidara Deal - Bloomberg.com
Merck seeks up to US$8 bil in US bond sale tied to Cidara deal — Bloomberg - The Edge Singapore
Geode Capital Management LLC Grows Stock Position in Cidara Therapeutics, Inc. $CDTX - MarketBeat
Intech Investment Management LLC Acquires Shares of 9,002 Cidara Therapeutics, Inc. $CDTX - MarketBeat
Street Watch: Why Cidara Therapeutics Inc. stock attracts high net worth investors - BỘ NỘI VỤ
3,783 Shares in Cidara Therapeutics, Inc. $CDTX Bought by Police & Firemen s Retirement System of New Jersey - MarketBeat
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer - AOL.com
Biotech Stocks To ConsiderNovember 25th - MarketBeat
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the MergerEXAS, SEE, CDTX, and MRSN - The Malaysian Reserve
hVIVO gains validation from Cidara’s takeover; broker calls it a "glowing endorsement" - Proactive Investors
Why Cidara Therapeutics Inc. stock attracts high net worth investors2025 Biggest Moves & Entry Point Confirmation Signals - BỘ NỘI VỤ
hVIVO PLCMSD to acquire Cidara - Research Tree
hVIVO welcomes MSD’s move to acquire Cidara in $9.2 billion deal - Vox Markets
hVIVO hails $9.2 billion Cidara takeover after key trial wins - Proactive financial news
Cidara Therapeutics Inc Stock (CDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cidara Therapeutics Inc Stock (CDTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ward Shane | COO & CLO |
Dec 10 '25 |
Sale |
220.08 |
9,959 |
2,191,747 |
25,033 |
| Davarpanah Nicole Negar | Chief Medical Officer |
Sep 11 '25 |
Sale |
62.86 |
474 |
29,797 |
31,418 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 26 '25 |
Buy |
44.00 |
2,272,727 |
99,999,988 |
3,365,523 |
| Mineo Chrysa | Director |
Jun 02 '25 |
Buy |
21.71 |
2,270 |
49,281 |
2,270 |
| Mineo Chrysa | Director |
Jun 03 '25 |
Buy |
23.44 |
1,050 |
24,614 |
3,320 |
| Ward Shane | COO & CLO |
Mar 11 '25 |
Sale |
21.96 |
1,664 |
36,542 |
14,674 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '25 |
Sale |
21.96 |
1,773 |
38,940 |
16,215 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):